The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease

British Journal of Clinical Pharmacology

Volumn 60, Issue 5, 2005, Pages 459-468

  Patterson, Dean ^a,e   Kloner, Robert ^b   Effron, Mark ^c   Emmick, Jeffrey ^c   Bedding, Alun ^c   Warner, Margaret ^c   Mitchell, Malcolm ^c   Braat, Simon ^d   MacDonald, Thomas ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Exercise induced ischaemia; Nitrate; Phosphodiesterase 5 inhibitors; Tadalafil

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; PLACEBO; TADALAFIL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG USE; ERECTILE DYSFUNCTION; EXPERIENCE; FEMALE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPOTENSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; RISK ASSESSMENT; SCREENING; SEXUAL BEHAVIOR; SITTING; ST SEGMENT DEPRESSION; SYSTOLIC BLOOD PRESSURE; TIME; TREADMILL EXERCISE;

AGED; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CARBOLINES; CORONARY ARTERIOSCLEROSIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NITROGLYCERIN; PHOSPHODIESTERASE INHIBITORS; VASODILATOR AGENTS;

EID: 27444439759     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02479.x     Document Type: Article

References (33)

1. Kloner RA, Mullin SH, Shook T, Matthews R, Mayeda G, Burstein S, Peled H, Rollick C, Choudhary R, Rosen R, Padma-Nathan H. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003; 170 (2 Part 2): S46-50; discussion S50.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates, results of the Massachusetts Male Aging Study. J Urol 1994; 151 (1): 54-61.
3. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9 (3): 123-6.
4. DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, Kostis JB, Kloner RA, Lakin M, Meston CM. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton consensus panel. The Am J Cardiol 2000; 86 (2): 175-81.
5. DeBusk RF. Evaluating the cardiovascular tolerance for sex. Am J Cardiol 2000; 86 (2A): 51F-56F.
6. Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM, Forrester JS, Douglas PS, Faxon DP, Fisher JD, Gibbons RJ, Halperin JL, Hochman JS, Kaul S, Weintraub WS, Winters WL Jr, Wolk MJ. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99 (1): 168-77.
7. Muller JE. Triggering of cardiac events by sexual activity, findings from a case-crossover analysis. Am J Cardiol 2000; 86 (2A): 14F-18F.
8. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. JAMA 1996; 275 (18): 1405-9.
9. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993; 329 (23): 1677-83.
10. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168 (4 Part 1): 1332-6.
11. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342 (24): 1802-13.
12. Kloner RMP, Segerson T. Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post hoc analysis of five placebo-controlled clinical trials. J Am Coll Cardiol 2003; 41: 276A-277A.
13. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol 1999; 83 (5A): 35C-44C.
14. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92 (9A): 37M-46M.
15. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92 (9A): 47M-57M.
16. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001; 14 (1): 70-3.
17. Bruce RA. Exercise testing methods and interpretation. Adv Cardiol 1978; 24: 6-15.
18. Hickey KBS, Weinsaft J, Shahzad A, Emmick JT, Bedding A, Costigan TM, Bergmann SR. Effect of Tadalafil, a phosphodiesterase 5 inhibitor, on myocardial blood flow in patients with coronary artery disease. J Am Coll Cardiol 2004; 43: 369A.
19. Thadani U, Smith W, Nash S, Bittar N, Glasser S, Narayan P, Stein RA, Larkin S, Mazzu A, Tota R, Pomerantz K, Sundaresan P. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol 2002; 40 (11): 2006-12.
20. Fox KM, Thadani U, Ma PT, Nash SD, Keating Z, Czorniak MA, Gillies H, Keltai M. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur Heart J 2003; 24 (24): 2206-12.
21. McInnis KJ, Balady GJ. Comparison of submaximal exercise responses using the Bruce vs modified Bruce protocols. Med Sci Sports Exerc 1994; 26 (1): 103-7.
22. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 287 (6): 719-25.
23. Vardi Y, Bulus M, Reisner S, Nassar S, Aboud L, Sprecher E, Gruenwald I. Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur Urol 2003; 43 (5): 544-51.
24. Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42 (10): 1855-60.
25. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36 (1): 25-31.
26. United States Food and Drug Administration. United States Package Insert (UPSI) for tadalafil; 2003.
27. Kjeldsen SE, Mundal R, Sandvik L, Erikssen G, Thaulow E, Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle-aged men. J Hypertens 2001; 19 (8): 1343-8.
28. Kurl S, Laukkanen JA, Rauramaa R, Lakka TA, Sivenius J, Salonen JT. Systolic blood pressure response to exercise stress test and risk of stroke. Stroke 2001; 32 (9): 2036-41.
29. Dorn J, Naughton J, Imamura D, Trevisan M. Prognostic value of peak exercise systolic blood pressure on long-term survival after myocardial infarction. Am J Cardiol 2001; 87 (2): 213-6. A8.
30. Tzemos N, Lim PO, MacDonald TM. Is exercise blood pressure a marker of vascular endothelial function? QJM 2002; 95 (7): 423-9.
31. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002; 40 (7): 1232-40.
32. Padma-nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002; 60 (2 Suppl 2): 67-90.
33. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT. Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sexual Med 2004; 1 (2): 161-7.